The US pharma industry saw a drop of 16.7% in overall deal activity during February 2019, when compared with the last 12-month average, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 65 deals worth $28.06bn were announced in February 2019, compared to the 12-month average of 78 deals.
Venture financing was the leading category in the month in terms of volume with 46 deals which accounted for 70.8% of all deals.
In second place was M&A with 14 deals, followed by private equity with five transactions, respectively accounting for 21.5% and 7.7% of overall deal activity in the country’s pharma industry during the month.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn terms of value of deals, M&A was the leading deal category in the US pharma industry with total deals worth $26.41bn, while venture financing and private equity deals totalled $1.04bn and $610.6m, respectively.
US pharma industry deals in February 2019: Top deals
The top five pharma industry deals accounted for 94.5% of the overall value during February 2019.
The combined value of the top five pharma industry deals stood at $26.51bn, against the overall value of $28.06bn recorded for the month. The top announced US pharma industry deal tracked by GlobalData in February 2019 was Danaher‘s $21.4bn asset transaction with General Electric.
In second place was the $4.3bn acquisition of Spark Therapeutics by F. Hoffmann-La Roche and in third place was TPG Capital and Vida Ventures’ $300m private equity deal with Kadiant.
The $300m acquisition of Immune Design by Merck Sharp & Dohme and Clinigen Group’s asset transaction with Novartis for $210m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
Verdict makes every effort to ensure the accuracy of its deals information. If you spot a mistake, or would like to notify us of a deal which should be included in this analysis, please email us at deals@globaldata.com
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
